JP2002541162A - 発作による脳障害防止法 - Google Patents

発作による脳障害防止法

Info

Publication number
JP2002541162A
JP2002541162A JP2000610293A JP2000610293A JP2002541162A JP 2002541162 A JP2002541162 A JP 2002541162A JP 2000610293 A JP2000610293 A JP 2000610293A JP 2000610293 A JP2000610293 A JP 2000610293A JP 2002541162 A JP2002541162 A JP 2002541162A
Authority
JP
Japan
Prior art keywords
seq
glycoprotein
human
ischemia
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000610293A
Other languages
English (en)
Japanese (ja)
Inventor
トレイシー、ケヴィン・ジェイ
ウォン、ハイチャオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Shore-Long Island Jewish Research Institute
Original Assignee
North Shore-Long Island Jewish Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Shore-Long Island Jewish Research Institute filed Critical North Shore-Long Island Jewish Research Institute
Publication of JP2002541162A publication Critical patent/JP2002541162A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2000610293A 1999-04-13 2000-04-13 発作による脳障害防止法 Withdrawn JP2002541162A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12928899P 1999-04-13 1999-04-13
US60/129,288 1999-04-13
PCT/US2000/010002 WO2000060943A1 (fr) 1999-04-13 2000-04-13 Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux

Publications (1)

Publication Number Publication Date
JP2002541162A true JP2002541162A (ja) 2002-12-03

Family

ID=22439301

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000610293A Withdrawn JP2002541162A (ja) 1999-04-13 2000-04-13 発作による脳障害防止法

Country Status (5)

Country Link
EP (1) EP1191845A4 (fr)
JP (1) JP2002541162A (fr)
AU (1) AU766910B2 (fr)
CA (1) CA2368937A1 (fr)
WO (1) WO2000060943A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005093412A1 (fr) * 2004-03-25 2005-10-06 Fuence Co., Ltd. Procédé de diagnostic d'une attaque d'apoplexie/d'un infarctus cérébral asymptomatique en utilisant le taux de polyamine et d’acroléine l’activité oxydase polyamine ou la teneur en protéine de celle-ci comme indication

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720311B2 (en) * 1997-12-18 2004-04-13 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
US20030044400A1 (en) * 2001-05-22 2003-03-06 Jenny Yu Composition and method for treating cells
EP4117706A1 (fr) 2020-03-11 2023-01-18 Universität Bern Fétuine a pour le traitement de troubles rénaux

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113164D0 (en) * 1991-06-18 1991-08-07 Ici Plc Pharmaceutical agent
SE520730C2 (sv) * 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005093412A1 (fr) * 2004-03-25 2005-10-06 Fuence Co., Ltd. Procédé de diagnostic d'une attaque d'apoplexie/d'un infarctus cérébral asymptomatique en utilisant le taux de polyamine et d’acroléine l’activité oxydase polyamine ou la teneur en protéine de celle-ci comme indication

Also Published As

Publication number Publication date
EP1191845A4 (fr) 2002-07-17
CA2368937A1 (fr) 2000-10-19
EP1191845A1 (fr) 2002-04-03
WO2000060943A1 (fr) 2000-10-19
AU766910B2 (en) 2003-10-23
AU4348500A (en) 2000-11-14

Similar Documents

Publication Publication Date Title
CA2515453C (fr) Procedes de traitement et de prevention des lesions tissulaires associees aux blessures par reperfusion ischemique
KR101508668B1 (ko) 허혈-재관류 손상의 예방을 위한 ｃ１ 억제제의 용도
ES2245028T3 (es) Uso de lactoferrina en el tratamiento de trastornos inducidos por alergenos.
JP2006518750A (ja) 胎便吸引症候群の治療のための方法および組成物
JP2010270156A (ja) 虚血性疾患の予防または治療剤
JP2002539174A (ja) 癌および血管新生関連の疾病の治療のためのｌｄｌ様受容体リガンドを使用する組成物および方法
WO2013059879A1 (fr) Compositions et procédés destinés au traitement de la fibrose et de maladies fibrogènes
WO2002099081A2 (fr) Methodes d'utilisation de facteurs de stimulation des colonies dans le traitement de tissus endommages et de l'ischemie
US20070032421A1 (en) Methods and compositions relating to cystatin C
JP2002541162A (ja) 発作による脳障害防止法
WO1999003493A1 (fr) Medicaments contenant midkine en tant principe actif ou inhibiteurs desdits medicaments
US20060216294A1 (en) Method of modulation
Bao et al. Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes
US7186555B1 (en) Prevention of brain damage in stroke
US6228363B1 (en) Peptides for the treatment of systemic lupus erythematosus
US6972175B2 (en) Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods
WO1992010200A1 (fr) Interactions fonctionnelles entre un glial s-100b et des neurones serotoninergiques du systeme nerveux central
P Sarapultsev et al. Effect of a new class of compounds of the group of substituted 5R1, 6H2-1, 3, 4-thiadiazine-2-amines on the inflammatory and cytokine response in experimental myocardial infarction
JPH03501562A (ja) 抗‐ｃ３ｂ１受容体（ｃｒ３）抗体および治療用組成物
JP6501251B2 (ja) 慢性疼痛の治療薬
JP3987943B2 (ja) 長時間虚血による脳組織ネクローシスの抑制剤
JP2003516362A (ja) 薬物におけるＴＮＦ−αおよびＣＤ９５Ｌの生物学的効果を阻害する化合物の組合せ
AU2003200309B2 (en) Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases
WO2023222051A1 (fr) Utilisation de mif et ripk1 pour des lésions cérébrales ischémiques périopératoires
JP2023178240A (ja) 自己免疫疾患の抑制用医薬組成物、自己抗体の産生抑制剤、及び異常免疫の調節剤

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20070703